This randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetics of RO5024048. Japanese and Caucasian healthy volunteers will be randomized to receive either single oral doses of RO5024048 or placebo. Follow-up is 7-10 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
97
Unnamed facility
Glendale, California, United States
Unnamed facility
Eatontown, New Jersey, United States
Pharmacokinetics of RO4995855 (parent of the prodrug RO5024048) and its metabolite(s)
Time frame: Day 1 to Day 4
Safety and tolerability: Adverse events, laboratory parameters, ECG
Time frame: Day 1 to Day 10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.